AZAYA Therapeutics, Inc. is an emerging technology company that is based in San Antonio, Texas. They began operations in 2003, and are a privately owned Delaware Corporation. AZAYA is using a novel, proprietary and widely applicable targeted nanotechnology platform aimed at developing safer and more effective cancer treatments for patients around the world. They received a patent for their Protein Stabilized Liposome (PSL) nanotechnology in February, 2007. This platform solves the significant problem associated with the formulation and delivery of water-insoluble active pharmaceutical ingredients, and has the potential to be applied to numerous therapeutic agents. Liposomes are small structures that they’re discovered in the early 1960s by British haematologist Dr. Alec D. Bangham. The name is derived from two Greek words: “LIPO” meaning fat and “SOMA” meaning body. They consist of an aqueous solution (a drug, for example) encapsulated by a hydrophobic membrane. Liposomes have unique properties that enable them to deliver drugs directly into targeted cells by “fusing” with the cell membrane and releasing the drug into the cell. In treating cancer, liposomes are very effective due to a mechanism referred to as the Enhanced Permeability and Retention (EPR) effect. Healthy human blood vessels are encased by tightly bound endothelial cells that do not permit any large particles to “leak” from the vessel into surrounding tissue. In patients with cancer, the blood vessels that support the growth of tumors do not have tightly bound endothelial cells, and “leakage” from the blood vessel into surrounding tissue occurs. Liposomes smaller than 200 nm in diameter are able to move from the blood vessel into the tumor, releasing the chemotherapy drug.